Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma

Published:2017-08 Issue:4 Volume:10 Page:511-517
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Dai Xiaomeng,Xue Jun,Hu Jianli,Yang Sheng-li,Chen George G.,Lai Paul B.S.,Yu Chao,Zeng Cui,Fang Xiefan,Pan Xiaoli,Zhang Tao

Funder

National Natural Science Foundation of China

Wuhan Planning Project of Science and Technology

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Global Cancer Statistics, 2012;Torre;CA Cancer J Clin,2015

2. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide;Perz;J Hepatol,2006

3. Targeted Therapies for Hepatocellular Carcinoma;Villanueva;Gastroenterology,2011

4. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma;Gao;Clin Cancer Res,2009

5. Depression, immunity, and survival in patients with hepatobiliary carcinoma;Steel;J Clin Oncol,2007

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress;Cancers;2024-05-11

2. HBV DNA polymerase upregulates the transcription of PD-L1 and suppresses T cell activity in hepatocellular carcinoma;Journal of Translational Medicine;2024-03-12

3. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma;BMC Cancer;2023-10-24

4. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma;BMC Cancer;2023-10-19

5. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma;Journal of Liver Cancer;2023-09-30